Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorJiménez-Yuste, Víctor
dc.contributor.authorÁlvarez Román, María Teresa
dc.contributor.authorPalomo Bravo, Ángeles
dc.contributor.authorGalmes, Bernardo J.
dc.contributor.authorNieto Hernández, Maria del Mar
dc.contributor.authorBenitez Hidalgo, Olga
dc.date.accessioned2022-08-11T06:09:06Z
dc.date.available2022-08-11T06:09:06Z
dc.date.issued2022-01
dc.identifier.citationJiménez-Yuste V, Alvarez-Román MT, Palomo Bravo Á, Galmes BJ, Nieto Hernández MDM, Benítez Hidalgo O, et al. Clinical Efficacy and Safety of Fanhdi®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study. Clin Appl Thromb Hemost. 2022 Jan;28:1–11.
dc.identifier.issn1938-2723
dc.identifier.urihttp://hdl.handle.net/11351/7986
dc.descriptionProphylaxis; Von willebrand disease
dc.description.abstractObjective To evaluate the efficacy and safety of a plasma-derived factor VIII concentrate containing von Willebrand Factor (pdVWF/FVIII) in standard clinical practice in von Willebrand Disease (VWD) patients. Methods A retrospective, multicentric, observational study of VWD patients treated with Fanhdi®, a pdVWF/FVIII concentrate, from January 2011 to December 2017 was conducted at 14 centers in Spain. Efficacy and safety were evaluated for acute bleeding episodes, for prevention of bleeding in surgeries, and for secondary long-term prophylaxis. Results Seventy-two eligible patients, type 1, 2, 3 VWD (25%/38.9%/36.1%) were treated for spontaneous and traumatic bleeding (140 episodes, n = 41 patients), to prevent surgical bleeding (69 episodes, n = 43 patients); and for secondary long-term prophylaxis (18 programs, n = 13 patients). Replacement therapy with pdVWF/FVIII showed an excellent to good clinical efficacy in 96.7% of the bleeding episodes, 100% during surgical procedures and 100% during prophylaxis. No adverse events (AEs), nor serious AEs related to the product were observed. Conclusions Fanhdi® was effective, safe and well tolerated in the management of bleeding episodes, the prevention of bleeding during surgeries, and for secondary long-term prophylaxis in VWD patients.
dc.language.isoeng
dc.publisherSAGE Publications
dc.relation.ispartofseriesClinical and Applied Thrombosis/Hemostasis;28
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectMalaltia de von Willebrandt - Tractament
dc.subjectSang - Coagulació - Factor VIII
dc.subject.meshvon Willebrand Diseases
dc.subject.meshvon Willebrand Factor
dc.subject.mesh/therapeutic use
dc.titleClinical Efficacy and Safety of Fanhdi®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1177/10760296221074348
dc.subject.decsenfermedades de von Willebrand
dc.subject.decsfactor de von Willebrand
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttps://doi.org/10.1177/10760296221074348
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Jiménez-Yuste V, Alvarez-Román MT] Department of Hematology and Hemotherapy, Hospital Universitario La Paz, Autónoma University, Madrid, Spain. [Palomo Bravo Á] Hematology Service, Hospital Materno-Infantil de Málaga, Málaga, Spain. [Galmes BJ] Hematology Service, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Nieto Hernández MDM] Hematology and Hemotherapy Service, Complejo Universitario de Jaén, Jaén, Spain. [Benítez Hidalgo O] Servei d’Hematologia i Hemoteràpia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid35108125
dc.identifier.wos000751874100001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record